SUIT-005 O2 pfi D011: Difference between revisions
From Bioblast
No edit summary |
No edit summary |
||
Line 4: | Line 4: | ||
|info='''A''': '''[[SUIT-005]]''' short protocol linked to [[SUIT-002 O2 pfi D006]] - '''SUIT RP2''' (human skeletal muscle) | |info='''A''': '''[[SUIT-005]]''' short protocol linked to [[SUIT-002 O2 pfi D006]] - '''SUIT RP2''' (human skeletal muscle) | ||
|application=O2 | |application=O2 | ||
|SUIT number=D011_1OctM;2D;3P;4S;5U;6Rot | |SUIT number=D011_1OctM;2D;3P;4S;5U;6Rot;7Ama;8AsTm;9Azd | ||
}} | }} | ||
::: '''[[Categories of SUIT protocols |SUIT-category]]:''' FNS(Oct,PM) | ::: '''[[Categories of SUIT protocols |SUIT-category]]:''' FNS(Oct,PM) | ||
Line 24: | Line 24: | ||
:::+ The presence of PM and S establishes a fully operative TCA cycle activity ([[PMS]]) if the 2-oxoglutarate carrier does not outcompete the sources of 2-oxoglutarate | :::+ The presence of PM and S establishes a fully operative TCA cycle activity ([[PMS]]) if the 2-oxoglutarate carrier does not outcompete the sources of 2-oxoglutarate | ||
:::+ Application of the [[cytochrome c]] test early in the protocol ensures comparability of all states in case of any effect of c. | :::+ Application of the [[cytochrome c]] test early in the protocol ensures comparability of all states in case of any effect of c. | ||
:::+ Reasonable duration of the experiment. | :::+ Reasonable duration of the experiment (1.5 to 2 h); 2-3 h when the CIV module is added. | ||
:::- F-[[OXPHOS-capacity| OXPHOS-capacity]] may be underestimated. In human heart muscle addition of Oct to palmitoylcarnitine (Pal) + malate increased OXPHOS by 26% (Lemuieux et al 2011). | :::- F-[[OXPHOS-capacity| OXPHOS-capacity]] may be underestimated. In human heart muscle addition of Oct to palmitoylcarnitine (Pal) + malate increased OXPHOS by 26% (Lemuieux et al 2011). | ||
:::- SRot<sub>''E''</sub> may be underestimated if S is not saturating. | :::- SRot<sub>''E''</sub> may be underestimated if S is not saturating. | ||
Revision as of 16:21, 4 March 2019
Description
Abbreviation: FNS(Oct,PM)
Reference: A: SUIT-005 short protocol linked to SUIT-002 O2 pfi D006 - SUIT RP2 (human skeletal muscle)
SUIT number: D011_1OctM;2D;3P;4S;5U;6Rot;7Ama;8AsTm;9Azd
O2k-Application: O2
- SUIT-category: FNS(Oct,PM)
- SUIT protocol pattern: diametral 1OctM;2D;3P;4S;5U;6Rot
- Linked to SUIT-002 O2 pfi D006 - SUIT RP2, specifically for human skeletal muscle mitochondria.
- Harmonized with SUIT-004 O2 pfi D010.
- F-pathway has to be tested previously.
Communicated by Doerrier C, Iglesias-Gonzalez J and Gnaiger E (last update 2019-01-21)
Steps and respiratory states
Step | State | Pathway | Q-junction | Comment - Events (E) and Marks (M) |
---|---|---|---|---|
1OctM | OctML(n) | F(N) | FAO | 1OctM
|
2D | OctMP | F(N) | FAO | 1OCtM;2D
|
2c | OctMcP | F(N) | FAO | 1OCtM;2D;2c
|
3P | OctPMP | FN | F&CI | 1OctM;2D;2c;3P
|
4S | OctPMSP | FNS | F&CI&II | 1OctM;2D;2c;3P;4S
|
5U | OctPMSE | FNS | F&CI&II | 1OctM;2D;2c;3P;4S;5U
|
6Rot | SE | S | CII | 1OctM;2D;3P;4S;5U;6Rot
|
7Ama | ROX | 1OctM;2D;3P;4S;5U;6Rot;7Ama
|
Step | Respiratory state | Pathway control | ET-Complex | Comment |
---|---|---|---|---|
## AsTm | AsTmE | CIV | CIV | |
## Azd | CHB |
- Bioblast links: SUIT protocols - >>>>>>> - Click on [Expand] or [Collapse] - >>>>>>>
- Coupling control
- Pathway control
- ยป Electron transfer pathway
- ยป Fatty acid oxidation pathway control state, F
- ยป NADH electron transfer-pathway state, N
- ยป Succinate pathway control state, S
- ยป NS-pathway control state, NS
- ยป Glycerophosphate pathway control state, Gp
- ยป Complex IV single step, CIV
- ยป Anaplerotic pathway control state
- Pathway control
- Main fuel substrates
- ยป Glutamate, G
- ยป Glycerophosphate, Gp
- ยป Malate, M
- ยป Octanoylcarnitine, Oct
- ยป Pyruvate, P
- ยป Succinate, S
- Main fuel substrates
- Glossary
Strengths and limitations
- + The protocol provides information on FAO capacity in the absence of other, potentially interfering pathways, both in the LEAK state and in OXPHOS.
- + FNS OXPHOS-capacity comprises the most important pathways in many cell types and thus provides a physiologically relevant estimate of maximum mitochondrial respiratory capacity.
- + FNS ET-capacity is a good estimate of overall ET-capacity in many cell types.
- + The presence of PM and S establishes a fully operative TCA cycle activity (PMS) if the 2-oxoglutarate carrier does not outcompete the sources of 2-oxoglutarate
- + Application of the cytochrome c test early in the protocol ensures comparability of all states in case of any effect of c.
- + Reasonable duration of the experiment (1.5 to 2 h); 2-3 h when the CIV module is added.
- - F- OXPHOS-capacity may be underestimated. In human heart muscle addition of Oct to palmitoylcarnitine (Pal) + malate increased OXPHOS by 26% (Lemuieux et al 2011).
- - SRotE may be underestimated if S is not saturating.
Compare SUIT protocols
- SUIT-002
- SUIT-002 O2 pfi D006
- imt, ROX: 1OctM;2D;2c;3P;4S;5U;6Rot;7Ama
- pfi, high O2, no ROX: FNS(PM)01_pfiO2,1OctM,2D(c),3P,4S,5U,6Rot
References
MitoPedia concepts: SUIT protocol, SUIT A, Find
MitoPedia methods:
Respirometry